Acrivon Therapeutics stockholders elect three Class II directors and ratify PwC as auditor at 2024 annual meeting

Acrivon Therapeutics, Inc.

Kristina Masson, Sharon Shacham, and Ivana Magovčević-Liebisch were elected as Class II directors with 24.6M, 23.3M, and 24.5M votes in favor, respectively.
PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal year 2024 with 27.4M for, 6,036 against, and 10,308 abstentions.
A quorum of 27.4M shares (88.81% of outstanding) was present or represented by proxy at the June 20, 2024 annual meeting.
Broker non-votes on director elections totaled approximately 2.7M shares, with none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.